JP2019534867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534867A5 JP2019534867A5 JP2019516407A JP2019516407A JP2019534867A5 JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5 JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019516407 A JP2019516407 A JP 2019516407A JP 2019534867 A5 JP2019534867 A5 JP 2019534867A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cannabidiol
- semi
- alkane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 8
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 4
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 4
- 229950011318 cannabidiol Drugs 0.000 claims 4
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 4
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 claims 2
- 108050007331 Cannabinoid receptor Proteins 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191194 | 2016-09-28 | ||
| EP16191194.6 | 2016-09-28 | ||
| EP17168172.9 | 2017-04-26 | ||
| EP17168172 | 2017-04-26 | ||
| PCT/EP2017/074545 WO2018060282A1 (en) | 2016-09-28 | 2017-09-27 | Compositions comprising a cannabinoid receptor binding ligand |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534867A JP2019534867A (ja) | 2019-12-05 |
| JP2019534867A5 true JP2019534867A5 (https=) | 2020-04-09 |
Family
ID=59966776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516407A Pending JP2019534867A (ja) | 2016-09-28 | 2017-09-27 | カンナビノイド受容体結合リガンドを含む組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190343793A1 (https=) |
| EP (2) | EP3518921B1 (https=) |
| JP (1) | JP2019534867A (https=) |
| KR (1) | KR20190060787A (https=) |
| CN (1) | CN109803650A (https=) |
| AU (1) | AU2017333420A1 (https=) |
| BR (1) | BR112019006194A2 (https=) |
| CA (1) | CA3036313A1 (https=) |
| MX (1) | MX2019003544A (https=) |
| WO (1) | WO2018060282A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| DK3181119T3 (da) | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| BR112016001522B1 (pt) | 2013-07-23 | 2019-10-01 | Novaliq Gmbh | Composições de anticorpo estabilizado |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| MX2018003781A (es) | 2015-09-30 | 2018-09-12 | Novaliq Gmbh | Compuestos semifluorados para administracion oftalmica. |
| EP3452150B1 (en) | 2016-05-03 | 2024-01-17 | Pneuma Respiratory, Inc. | Droplet delivery device for delivery of fluids to the pulmonary system |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| US10732712B2 (en) * | 2016-12-27 | 2020-08-04 | Facebook Technologies, Llc | Large scale integration of haptic devices |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111526914A (zh) | 2017-10-04 | 2020-08-11 | 精呼吸股份有限公司 | 电子呼吸致动式直线型液滴输送装置及其使用方法 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| JP2021502178A (ja) | 2017-11-08 | 2021-01-28 | ニューマ・リスパイラトリー・インコーポレイテッド | 小容積アンプルを有して呼吸により電気的に作動するインライン液滴送達装置および使用方法 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| KR102882058B1 (ko) | 2018-03-28 | 2025-11-07 | 노바리크 게엠베하 | 티몰롤을 포함하는 약제학적 조성물 |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| JP7665519B2 (ja) * | 2019-02-01 | 2025-04-21 | アルコン インコーポレイティド | 近視を治療するための化合物、組成物及び医薬組成物 |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| MX2022014459A (es) | 2020-05-18 | 2023-02-27 | Max Biology Co Ltd | Composiciones de lipidos y polimeros y metodos de uso. |
| EP4203716A1 (en) * | 2020-09-24 | 2023-07-05 | Nicoventures Trading Limited | Formulation |
| CA3194409A1 (en) * | 2020-10-05 | 2022-04-14 | Sunil Shah | Cannabinoid-containing compositions and use for treating and preventing diseases |
| US11191751B1 (en) * | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
| JP7749020B2 (ja) | 2021-02-03 | 2025-10-03 | エーディーエス・セラピューティクス・エルエルシー | 局所眼科用組成物 |
| US11793945B2 (en) | 2021-06-22 | 2023-10-24 | Pneuma Respiratory, Inc. | Droplet delivery device with push ejection |
| US20250228876A1 (en) * | 2021-10-13 | 2025-07-17 | Pneuma Respiratory, Inc. | Compositions for delivery of cannabinoids |
| CN119768202A (zh) | 2022-07-18 | 2025-04-04 | 精呼吸股份有限公司 | 小步长高分辨率气溶胶生成系统及方法 |
| WO2026037894A1 (en) * | 2024-08-15 | 2026-02-19 | Dermaliq Therapeutics, Inc. | Semifluorinated alkane compositions for cleaning the skin |
| WO2026047389A1 (en) * | 2024-08-30 | 2026-03-05 | Vicadia Lda | Topical delivery of cannabinoid-based formulations for ocular allergy and inflammation in ophthalmic diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| WO2008019146A2 (en) | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| PL2352497T3 (pl) | 2008-10-31 | 2017-08-31 | University Of Mississippi | Proces przygotowania estrów aminokwasowych delta-9-thc |
| AT509000B1 (de) * | 2009-10-23 | 2012-12-15 | Rausch Peter | Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| EP2444063A1 (en) * | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
| CN113679697A (zh) * | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| DK3181119T3 (da) * | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| US9265809B2 (en) | 2013-10-09 | 2016-02-23 | Johnson Living Trust dated October 26, 2011, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| CA2931039C (en) * | 2013-11-20 | 2022-07-12 | Mary Lynch | Compositions and methods for treatment of ocular inflammation and pain |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
-
2017
- 2017-09-27 AU AU2017333420A patent/AU2017333420A1/en not_active Abandoned
- 2017-09-27 MX MX2019003544A patent/MX2019003544A/es unknown
- 2017-09-27 KR KR1020197010976A patent/KR20190060787A/ko not_active Ceased
- 2017-09-27 CA CA3036313A patent/CA3036313A1/en not_active Withdrawn
- 2017-09-27 JP JP2019516407A patent/JP2019534867A/ja active Pending
- 2017-09-27 US US16/337,617 patent/US20190343793A1/en not_active Abandoned
- 2017-09-27 EP EP17772438.2A patent/EP3518921B1/en active Active
- 2017-09-27 EP EP20159519.6A patent/EP3698785A1/en not_active Withdrawn
- 2017-09-27 CN CN201780058931.9A patent/CN109803650A/zh not_active Withdrawn
- 2017-09-27 WO PCT/EP2017/074545 patent/WO2018060282A1/en not_active Ceased
- 2017-09-27 BR BR112019006194A patent/BR112019006194A2/pt not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534867A5 (https=) | ||
| Sambhara et al. | Glaucoma management: relative value and place in therapy of available drug treatments | |
| JP2018529693A5 (https=) | ||
| JP7042274B2 (ja) | 眼内炎症性眼疾患の治療のためのタクロリムスを含む組成物 | |
| JP2015531344A5 (https=) | ||
| JP2019532931A5 (https=) | ||
| JP2018531233A5 (https=) | ||
| JP6824270B2 (ja) | 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子 | |
| JP2020517622A5 (https=) | ||
| JP2021518352A5 (https=) | ||
| IL273531B2 (en) | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases | |
| ES2540151B1 (es) | Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico | |
| EP3397255A1 (en) | Compositions for the treatment of presbyopia | |
| JP2009137971A (ja) | 薬剤および薬剤キット | |
| JP7787129B2 (ja) | 眼科組成物 | |
| ES2324130B1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular. | |
| US20230043428A1 (en) | Compositions and methods for use of cannabinoids for neuroprotection | |
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| US9187468B2 (en) | Topical ocular analgesic agents | |
| WO2016182032A1 (ja) | アゾール系抗真菌薬の眼瞼皮膚への投与 | |
| JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
| JP3142559B2 (ja) | 止痒剤としての血小板活性化因子拮抗剤の用途 | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| RU2836815C1 (ru) | Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования | |
| JP7417531B2 (ja) | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 |